The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
Open accessPublished version of a preprint
Abstract
Purpose: PF299804 is a potent, orally available, irreversible inhibitor of tyrosine kinase human epidermal growth factor receptors (HER) 1 (EGFR), HER2, and HER4. This first-in-human study investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF299804 in patients with advanced solid malignancies. Experimental Design: PF299804 was administered once daily continuously (schedule A) and intermittently (schedule B). Dose escalation proceeded until intolerable toxicities occurred. Skin biopsies were taken predose and after 14 days of treatment to establish a pharmacokinetic/pharmacodynamic relationship. Tumor response was measured once every 2 cycles. Efficacy was correlated with tumor genotypes in non–small cell lung cancer (NSCLC) patients. Results: 121 patients were included (111 in schedule A, 10 in schedule B). The maximum tolerated dose (MTD) was 45 mg/d. Dose-limiting toxicities included stomatitis and skin toxicities. Most adverse events were mild and comprised skin toxicities, fatigue, and gastrointestinal side-effects including diarrhea, nausea, and vomiting. Pharmacokinetic analyses revealed dose-dependent increases in PF299804 exposure associated with target inhibition in skin biopsy samples. Fifty-seven patients with non–small cell lung cancer (NSCLC) were treated in this study. Four patients, all previously treated with gefitinib or erlotinib (2 with exon 19 deletions, 1 with exon 20 insertion, 1 mutational status unknown), had a partial response to PF299804. Conclusions: The MTD of PF299804 is 45 mg/d. Both continuous and intermittent treatment schedules were well tolerated, and encouraging signs of antitumor activity were observed in gefitinib/erlotinib treated NSCLC patients. Clin Cancer Res; 17(5); 1131–9. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In concordance with this, clinical testing of afatinib, neratinib, and dacomitinib achieved overall response rates of 8.7%, 9.5%, and 12%, respectively, for patients harboring EGFR or HER2 exon 20 mutations25,42,46,47.”
From Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer (2018) · cites this paper as [42]
In the citing paper
“By contrast, other first-, second-, and third-generation TKIs had IC50 values that were above the clinically achievable plasma concentrations previously observed in patients31,41,42,43,44,45.”
From Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer (2018) · cites this paper as [42]
In the citing paper
“Non-small cell lung cancer (NSCLC) patients with tumors harboring these mutations seldom achieve clinical responses to dacomitinib and afatinib, two covalent quinazoline-based inhibitors of EGFR or HER2, respectively.”
From Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors (2017) · cites this paper as [25]
In the citing paper
“Some of these patients were enrolled in clinical trials of dacomitinib treatment, and one patient with D770delinsGY showed partial response (25).”
From Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors (2017) · cites this paper as [25]
In the citing paper
“In the phase I study of dacomitinib, 6 patients with EGFR exon 20 insertions were treated and 1 of 6 patients had a sustained PR (25).”
From Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors (2017) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationGefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P. M., Lynch, T. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502860102 · Cited by 966
Cited by
Sorted by citations
Items 101–179 of 179
Dacomitinib in Non-Small-Cell Lung Cancer: A Comprehensive Review for Clinical Application
Sun, H., & Wu, Y.-L. L. C. (2019) · Future Oncology · doi:10.2217/fon-2018-0535 · Cited by 19
Dacomitinib, an emerging HER-targeted therapy for non-small cell lung cancer.
Carpenter, R. L., & Lo, H. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2012.10.09 · Cited by 17
Recent advances in targeted advanced lung cancer therapy in the elderly
Losanno, T., & Gridelli, C. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1348232 · Cited by 16
Sattler, M., Mambetsariev, I., Fricke, J., Tan, T., Liu, S., Vaidehi, N., Pisick, E. P., Mirzapoiazova, T., Rock, A. G., Merla, A., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051936 · Cited by 16
Cernomaz, A. T., Macovei, I. I., Pavel, I., Grigoriu, C., Marinca, M. V., Baty, F., Péter, S., Zonda, R., Brutsche, M. H., & Grigoriu, B. D. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0250-0 · Cited by 16
Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications
Quintanal-Villalonga, À., Paz-Ares, L. G., Ferrer, I., & Molina‐Pinelo, S. (2016) · Disease Markers · doi:10.1155/2016/9214056 · Cited by 16
Santarpía, M., Menis, J., CHAIB-OUKADOUR, I., Cao, M. G., & Rosell, R. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1649136 · Cited by 16
Qiu, X., Lin, Q., Ning, Z., Qian, X., Li, P., Ye, L., & Xie, S. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.12.041 · Cited by 15
Li, H., Yang, G., Cai, Y., Li, J., Xu, H., Zhang, T., Zhou, L., Wang, Y., Wang, J., Hu, X., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.919652 · Cited by 17
Wang, Y., Guo, Z., Yang, L., & Zhou, Q. (2016) · Open Medicine · doi:10.1515/med-2016-0014 · Cited by 16
Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
Wu, W.-S., & Chen, Y. (2014) · Journal of Personalized Medicine · doi:10.3390/jpm4030297 · Cited by 14
Chiu, J. W. Y., Chan, K., Chen, E. X., Siu, L. L., & Razak, A. R. A. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0245-3 · Cited by 14
Williams, J. P., Kim, I., Ito, E., Shi, W., Yue, S., Siu, L. L., Waldron, J. N., O’Sullivan, B., Yip, K. W., & Liu, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098557 · Cited by 13
Effects of CYP2D6 Genetic Polymorphism and Drug Interaction on the Metabolism of Dacomitinib
Han, M., Zhang, X., Ye, Z., Wang, J., Kong, Q., Hu, X., Qian, J., Cai, J., & Hu, G. (2021) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.1c00327 · Cited by 13
Kim, D., Garon, E. B., Jatoi, A., Keefe, D. M. K., Lacouture, M. E., Sonis, S. T., Gernhardt, D., Wang, T., Giri, N., Doherty, J. P., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.01.021 · Cited by 13
Self-citationKobayashi, I. S., Viray, H., Rangachari, D., Kobayashi, S. S., & Costa, D. B. (2021) · Cells · doi:10.3390/cells10123561 · Cited by 12
Pu, X., Zhou, Y. L., Kong, Y., Chen, B., Yang, A., Li, J., Li, K., Xu, Y., & Wu, L. (2023) · BMC Cancer · doi:10.1186/s12885-023-11465-2 · Cited by 14
Zugazagoitia, J., Díaz, A., Jiménez, E., Nuñez, J. A., Iglesias, L., Ponce-Aix, S., & Paz-Ares, L. G. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00036 · Cited by 12
Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress
Castellanos, E. H., & Horn, L. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0365-1 · Cited by 12
Berlin, J. D., Tolcher, A. W., Ding, C., Whisenant, J. G., Horak, I. D., Wood, D. L., Nadler, P. I., Hansen, U. H., Lantto, J., Skartved, N. J. Ø., et al. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01217-7 · Cited by 11
Unveiling changes in the landscape of patient populations in cancer early drug development
Hierro, C., Azaro, A., Argilés, G., Élez, E., Gómez, P., Carles, J., & Rodon, J. A. (2016) · Oncotarget · doi:10.18632/oncotarget.13258 · Cited by 11
A novel treatment strategy for EGFR mutant NSCLC with T790M‐mediated acquired resistance
Taube, E., Jokinen, E., Koivunen, P., & Koivunen, J. P. (2011) · International Journal of Cancer · doi:10.1002/ijc.26461 · Cited by 11
Prawira, A., Braña, I., Spreafico, A., Hope, A. J., Waldron, J. N., Razak, A. R. A., Chen, E. X., Jang, R., O’Sullivan, B., Giuliani, M., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0367-2 · Cited by 11
Dacomitinib for the Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer
Mok, T. S. K., Lee, K., Tang, M., & Leung, L. K. S. (2014) · Future Oncology · doi:10.2217/fon.14.22 · Cited by 10
Zhu, L., Lopez, S., Bellone, S., Black, J., Cocco, E., Zigras, T., Predolini, F., Bonazzoli, E., Bussi, B., Stuhmer, Z., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-3218-4 · Cited by 10
Li, H., Li, J., Yan, X., Xu, H., Zhou, L., Hu, X., Wang, Y., Lei, S., & Wang, Y. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-21-1841 · Cited by 9
Yu, H. A., Ahn, M., Cho, B. C., Gerber, D. E., Natale, R. B., Socinski, M. A., Giri, N., Quinn, S., Sbar, E. I., Zhang, H., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.08.017 · Cited by 10
Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
Lin, L., Wu, X., Yan, S., Zhu, Y., Yan, Z., Lv, D., & Ge, H. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s268694 · Cited by 10
Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer
Kim, D. W. N., Nam, T., Choe, K. S., & Choy, H. (2012) · Cancer Research and Treatment · doi:10.4143/crt.2012.44.2.74 · Cited by 10
Skrzypski, M. T., Szymanowska-Narloch, A., & Dziadziuszko, R. (2017) · Współczesna Onkologia · doi:10.5114/wo.2017.70116 · Cited by 9
Yang, G., Yang, Y., Hu, J., Xu, H., Zhang, S., & Wang, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.984503 · Cited by 11
Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer
Reungwetwattana, T., Rohatgi, N., Mok, T. S. K., & Prabhash, K. (2021) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1909420 · Cited by 9
Martinez, R. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2018.12.003 · Cited by 8
Feng, X., Ding, Y., Zhang, P., Fu, Q., Zhang, L., & Zheng, H. (2021) · Journal of Chromatography B · doi:10.1016/j.jchromb.2021.122940 · Cited by 7
Novel Antineoplastics Targeting Genetic Changes in Colorectal Cancer
Joudeh, J., Allen, J. E., Das, A., Prabhu, V. V., Farbaniec, M., Adler, J. M., & El‐Deiry, W. S. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-6176-0_1 · Cited by 8
Xie, Z., Chen, X., Gao, R., Yang, M., Han, X., Sun, Y., & Shi, Y. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004016 · Cited by 8
Yang, L., Luo, X.-Z., Xie, L., Lei, X.-Z., & Zhu, J. (2023) · Translational Cancer Research · doi:10.21037/tcr-23-95 · Cited by 6
Chen, X., Jiang, J., Giri, N., & Hu, P. (2017) · Xenobiotica · doi:10.1080/00498254.2017.1342881 · Cited by 7
Targeted therapy sensitivity and resistance in solid malignancies
Jokinen, E. (2014) · Cited by 6
Wang, X., Goldstein, D., Crowe, P. J., & Yang, J. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4337 · Cited by 6
Karikios, D. J., & Boyer, M. J. (2012) · Clinical Investigation · doi:10.4155/cli.12.7 · Cited by 6
Current Role of Dacomitinib in Head and Neck Cancer
Eliçin, O., & Özşahin, M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1177022 · Cited by 6
Sebille, Y. Z. A. V., Gibson, R. J., Wardill, H. R., & Bowen, J. M. (2016) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000210 · Cited by 6
Tan, W., Giri, N., Quinn, S., Wilner, K. D., & Parivar, K. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00887-0 · Cited by 6
Karachaliou, N., & Rosell, R. (2014) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s50671 · Cited by 6
Targeting exon 20 insertion mutations in lung cancer
Yang, Y., & Wang, Y. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000919 · Cited by 5
Mutukuru, M., Kandula, S. R., Ramakrishna, V., Sanka, P., Sidde, G. P., Muzzamil, S. M., Uppara, H. B., & Prasad, P. D. (2026) · International Journal of Cancer · doi:10.1002/ijc.70318 · Cited by 4
Cunningham, D., Okines, A. F. C., & Cunningham, D. (2011) · Gastrointestinal Cancer Targets and Therapy · doi:10.2147/gictt.s18495 · Cited by 4
Garzón‐Ibáñez, M., Reyes, R., Molina‐Vila, M. Á., & Sullivan, I. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03899-w · Cited by 4
Uğurluer, G., & Özşahin, M. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.951435 · Cited by 4
Anti-EGFR Therapy in Gallbladder Cancer
Bains, L., & Chawla, T. (2023) · Springer eBooks · doi:10.1007/978-981-19-6442-8_18 · Cited by 4
Yi, H.-L., Yang, R.-P., Tang, Q. H., Tao, Z., & Huang, Y. (2023) · Analytica Chimica Acta · doi:10.1016/j.aca.2023.342124 · Cited by 3
Biomarkeranalytik aus Sicht des Pathologen
Buettner, R., & Heydt, C. (2013) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-013-1823-1 · Cited by 3
Li, J., Xue, Y., Wang, X., Smith, L. S., He, B., Liu, S., & Zhu, H. (2022) · Clinical and Translational Science · doi:10.1111/cts.13400 · Cited by 3
The potential role of new targeted therapies in the treatment of advanced non-small-cell lung cancer
Casaluce, F., Sgambato, A., Maione, P., Rossi, A., Ferrara, C., Napolitano, A., Palazzolo, G., Ciardiello, F., & Gridelli, C. (2013) · Clinical Investigation · doi:10.4155/cli.13.14 · Cited by 3
Alossaimi, M. A., Aldakhil, T., Elmansi, H., Belal, F. F., & Magdy, G. (2026) · RSC Advances · doi:10.1039/d5ra09242f · Cited by 2
Hamada, A., Suda, K., Koga, T., Fujino, T., Nishino, M., Ohara, S., Chiba, M., Shimoji, M., Takemoto, T., Soh, J., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.10.014 · Cited by 3
Boyer, M. J., Janne, P. A., Mok, T. S. K., O'Byrne, K. J., Paz-Ares, L. G., Ramalingam, S. S., Liang, J. Q., Taylor, I. W., Campbell, A., O'Connell, J. P., et al. (2012) · Clinical Investigation · doi:10.4155/cli.12.137 · Cited by 2
Self-citationPoor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma
Inagaki, Y., Tamiya, A., Matsuda, Y., Azuma, K., Adachi, Y., Enomoto, T., Kouno, S., Taniguchi, Y., Saijo, N., Okishio, K., et al. (2020) · Medicine · doi:10.1097/md.0000000000022628 · Cited by 2
Torres, L. L., Puentes, N. C., & Alviz-Amador, A. (2021) · Revista Ciencias Biomédicas · doi:10.32997/rcb-2021-3666 · Cited by 2
EGFR exon 20 insertion in non-small cell lung cancer
Panda, G. S., Noronha, V., Shetty, O. A., Yadav, S. C., Kumar, R., Patil, V., Chandrani, P., Janu, A., Mahajan, A., Chougule, A., et al. (2022) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_77_22 · Cited by 2
Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib
Liu, J., Lin, S., Huynh, A., & Tan, W. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16010118 · Cited by 1
Novel oral anticancer drugs: a review of adverse drug reactions, interactions and patient adherence
Bartal, A., Mátrai, Z., Szűcs, A. L., Belinszkaja, G., Langmár, Z., & Rosta, A. (2012) · Orvosi Hetilap · doi:10.1556/oh.2012.29272 · Cited by 1
Nelson, E. L. (2014) · Clinical Investigation · doi:10.4155/cli.14.63 · Cited by 1
Liu, K., Tan, Q., Fang, N., Niu, L., Guo, N., Du, W., Jiang, G., Cai, Y., Tan, Q., Wu, L., et al. (2021) · Clinical Medicine Insights Oncology · doi:10.1177/11795549261454548 · Cited by 1
Mechanisms of Resistance to Epidermal Growth Factor Receptor (EGFR) in Non‐Small Cell Lung Cancer
Massarelli, E. (2014) · Lung Cancer · doi:10.1002/9781118468791.ch27 · Cited by 1
Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer
Mirone, G., Perna, S., & Marfè, G. (2016) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-46091-8_2
Aktuelle Entwicklung der molekular zielgerichteten Therapie von Kopf-Hals-Karzinomen
Strieth, S., & Ernst, B. P. (2017) · Laryngo-Rhino-Otologie · doi:10.1055/s-0037-1600927
Babu, M., Babu, K. G., Lokesh, K. N., Rajeev, L. K., & Bhat, G. R. (2017) · Asian Journal of Oncology · doi:10.4103/2454-6798.209336
Systemic Options for Second-Line Therapy and Beyond
Goss, G. D., & Mok, T. S. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52357-8.00045-7
Grigorescu, A. C., & Mihaela, T. L. (2020) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v10i1.3830
[Studies and Progress of EGFR exon 20 Insertion Mutation in Non-small Cell Lung Cancer].
Zhou, W., Zhang, W., & Han, B. (2020) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2020.02.07
Translational research of combined anticancer therapies targeting the MAPK pathway
Huijberts, S. C. F. A. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/1019
Hedstrom, L. (2014) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.718209847.793489150
Liu, G., Xue, J., Wang, Y., Liu, Z., Li, X., Qu, D., Su, Z., Xu, K., Qu, X., Qu, Z., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04148-1
A Detouring Experience Not Recommended: Lessons Learned from PF00299804
Li, M. S. C., Mok, K. K. S., & Mok, T. S. K. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2638
Sumesgutner, D., Brunmayr, P., Gopko, V., Dobersberger, M., & Traxlmayr, M. W. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.153165
Grivas, P. D., Day, K. C., Karatsinides, A., Paul, A., Shakir, N., Owainati, I., Liebert, M., Kunju, L. P., Thomas, D., Hussain, M., et al. (2013) · Figshare · doi:10.6084/m9.figshare.7193816
Pu, X., Zhou, Y., Kong, Y., Chen, B., Yang, A., Li, J., Li, K., Xu, Y., & Wu, L. (2024) · Figshare · doi:10.6084/m9.figshare.26627242
Metadata
- Authors
- Jänne, P. A., Boss, D. S., Camidge, D. R., Britten, C. D., Engelman, J. A., Garon, E. B., Guo, F., Wong, S., Liang, J., Letrent, S., Millham, R., Taylor, I., Eckhardt, S. G., & Schellens, J. H. M.
- Affiliations
- Authors' Affiliations: 1Dana Farber Cancer Institute and 2Massachusetts General Hospital Cancer Center, Boston, Massachusetts; 3Netherlands Cancer Institute, Division of Clinical Pharmacology, Amsterdam, The Netherlands; 4University of Colorado, Denver, Aurora, Colorado; 5University of California Los Angeles, UCLA Medical Center, Los Angeles, California; 6Clinical Pharmacology and Pharmacometrics, Pfizer (China) Research and Development Center, Shanghai, P.R. China; 7Pfizer Oncology, New London, Connecticut; 8Clinical Development and Medical Affairs, Pfizer Oncology, San Diego, California; and 9Faculty of Pharmaceutical Sciences, Division of Drug Toxicology, University Utrecht, Utrecht, the Netherlands
- University of California, Los Angeles (US)
- Venue
- Clinical Cancer Research
- Published
- 2011-03-01
- Volume
- 17
- Issue
- 5
- Pages
- 1131-1139
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC3048920
- OpenAlex
- W2161152839
- Cited by
- 181
- References
- 23
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 2 · 2023: 6 · 2022: 12 · 2021: 13 · 2020: 10 · 2019: 10 · 2018: 14 · 2017: 12 · 2016: 14 · 2015: 18 · 2014: 18 · 2013: 22 · 2012: 18
- FWCI
- 17.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Pfizer
- National Institutes of Health
- National Cancer Institute (P50CA090578, R01CA135257)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- pan-HER inhibitor, EGFR, HER2, ErbB4, tyrosine kinase inhibitors, dose escalation, maximum tolerated dose, non-small cell lung cancer, stomatitis, skin toxicity, pharmacokinetics, pharmacodynamics, exon 19 deletion, exon 20 insertion, anticancer activity
- MeSH terms
- Erlotinib Hydrochloride, Gefitinib, Adult, Aged, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Genotype, Heptanoic Acids, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Protein-Tyrosine Kinases, Pyrazoles, Quinazolines, Biomarkers, Tumor, Signal Transduction, Treatment Outcome, Erb-b2 Receptor Tyrosine Kinases, Maximum Tolerated Dose, ErbB Receptors, Receptor, ErbB-4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
